Cas:1001907-60-3 (1-methyl-1H-indazol-4-yl)boronic acid manufacturer & supplier

Chemical Name:(1-methyl-1H-indazol-4-yl)boronic acid

CAS.NO:1001907-60-3

Synonyms:(1-Methyl-1H-indazol-4-yl)boronic acid;(1-methylindazol-4-yl)boronic acid

Molecular Formula:C₈H₉BN₂O₂

Molecular Weight:175.98000

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:397.5ºC at 760 mmHg

Density:1.27 g/cm3

Index of Refraction:

PSA:58.28000

Exact Mass:176.07600

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (1-Methyl-1H-indazol-4-yl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(1-methylindazol-4-yl)boronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1-Methyl-1H-indazol-4-yl)boronic acid Use and application,(1-methylindazol-4-yl)boronic acid technical grade,usp/ep/jp grade.

Related News: A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. (1-methyl-1H-indazol-4-yl)boronic acid manufacturer As United Airlines said when suspended flights to Beijing, Shanghai and Chengdu, the decision was made due to the continued drop in demand for travel to China and the US Department of State��s decision to raise its China travel advisory to a Level 4. (1-methyl-1H-indazol-4-yl)boronic acid supplier As United Airlines said when suspended flights to Beijing, Shanghai and Chengdu, the decision was made due to the continued drop in demand for travel to China and the US Department of State��s decision to raise its China travel advisory to a Level 4. (1-methyl-1H-indazol-4-yl)boronic acid vendor A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. (1-methyl-1H-indazol-4-yl)boronic acid factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.